Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.
Merck & Co., Inc. operates as a healthcare company worldwide. Based in Rahway, United States the company has 70,000 full time ...
RAHWAY, N.J., January 16, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, ...
EVX-01 is designed with Evaxion’s AI-Immunology™ platform and tailored to target the unique tumor profile and immune ...
Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...
With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare industry, operating through its Pharmaceutical and Animal Health segments.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president ...
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...